We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

120 hedge funds and large institutions have $1.5B invested in Agios Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 32 increasing their positions, 33 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

124% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 17

39% more capital invested

Capital invested by funds: $1.08B → $1.5B (+$420M)

21% more funds holding

Funds holding: 99 → 120 (+21)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

3% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 33

51% less call options, than puts

Call options by funds: $6.06M | Put options by funds: $12.3M

Holders
120
Holders Change
+21
Holders Change %
+21.21%
% of All Funds
3.48%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.17%
New
38
Increased
32
Reduced
33
Closed
17
Calls
$6.06M
Puts
$12.3M
Net Calls
-$6.23M
Net Calls Change
-$5.35M

Top Buyers

Rank Fund Capital Flow
1
BB
BB Biotech
Switzerland
+$59.7M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$24.8M
3
State Street
State Street
Massachusetts
+$16M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$9.52M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.85M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$46.7M
2
TRV
Third Rock Ventures
Massachusetts
-$35.6M
3
HLA
Hamilton Lane Advisors
Pennsylvania
-$11.4M
4
SOMRS
State of Michigan Retirement System
Michigan
-$10.9M
5
GE
General Electric
Ohio
-$7.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
TG
51
TCW Group
California
$2.08M -$74K -1,717 -5%
EI
52
EAM Investors
California
$1.81M -$498K -11,547 -28%
SGAM
53
Smith Group Asset Management
Texas
$1.77M -$2.59K -60 -0.2%
HLA
54
Hamilton Lane Advisors
Pennsylvania
$1.69M -$11.4M -264,357 -91%
BlackRock
55
BlackRock
New York
$1.69M -$1.53M -35,494 -56%
U
56
UBS
Switzerland
$1.59M +$1.03M +23,966 +1,255%
Charles Schwab
57
Charles Schwab
California
$1.56M +$13K +301 +1%
California State Teachers Retirement System (CalSTRS)
58
California State Teachers Retirement System (CalSTRS)
California
$1.54M +$10.4K +242 +1%
Ameriprise
59
Ameriprise
Minnesota
$1.44M -$599K -13,888 -37%
AllianceBernstein
60
AllianceBernstein
Tennessee
$1.42M -$345K -8,000 -26%
ProShare Advisors
61
ProShare Advisors
Maryland
$1.42M -$176K -4,088 -15%
NFA
62
Nationwide Fund Advisors
Ohio
$1.37M +$1.98K +46 +0.2%
Millennium Management
63
Millennium Management
New York
$1.32M +$931K +21,600 New
TRSOTSOK
64
Teachers Retirement System of the State of Kentucky
Kentucky
$1.31M – – –
Goldman Sachs
65
Goldman Sachs
New York
$1.25M +$652K +15,136 +287%
GTC
66
Ghost Tree Capital
New York
$1.23M +$862K +20,000 New
PP
67
PDT Partners
New York
$1.22M +$858K +19,900 New
RFC
68
Russell Frank Company
Washington
$1.18M -$350K -8,129 -30%
TA
69
Teachers Advisors
New York
$1.16M – – –
RCM
70
RA Capital Management
Massachusetts
$1.08M +$759K +17,600 New
New York State Common Retirement Fund
71
New York State Common Retirement Fund
New York
$1.07M – – –
Renaissance Technologies
72
Renaissance Technologies
New York
$975K +$685K +15,900 New
Swiss National Bank
73
Swiss National Bank
Switzerland
$945K – – –
AQR Capital Management
74
AQR Capital Management
Connecticut
$859K +$603K +14,000 New
SO
75
STRS Ohio
Ohio
$834K +$586K +13,600 New
1 2
3
4 5

AGIO Hedge Fund Activity: Q3 2014 in Review

120 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2014, worth a combined $1.5B — up 39% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new AGIO positions and 17 closed out — a net gain of 21 holders — while 32 added to existing stakes and 33 trimmed.

The largest buyer was BB Biotech, adding an estimated $59.7M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $46.7M sold.

  • 120 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2014, up from 99 in Q2 2014.
  • Funds reported $1.5B of Agios Pharmaceuticals stock for Q3 2014, up 39% quarter-over-quarter.
  • 38 funds opened new Agios Pharmaceuticals positions in Q3 2014 and 17 closed out, a net change of +21 holders.
  • The largest Agios Pharmaceuticals buyer in Q3 2014 was BB Biotech, an estimated $59.7M added.
  • The largest Agios Pharmaceuticals seller in Q3 2014 was T. Rowe Price Associates, an estimated $46.7M sold.

Based on aggregated 13F filings for Q3 2014.